Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 151 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Saline - Day 21 Clear all
Completed Phase 2 Interventional Results available

Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

NCT01006369
View directory record Official record
Conditions
Colorectal Cancer
Interventions
hydroxychloroquine
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 120 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
4
States / cities
Camden, New Jersey • Hamilton, New Jersey • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Sep 25, 2026, 4:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design

NCT06369675
View directory record Official record
Conditions
Erythema
Interventions
MOB015B, 0.2% SLS, 0.9% Saline, MOB015B vehicle
Drug
Lead sponsor
Moberg Pharma AB
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Sep 25, 2026, 4:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)

NCT03410030
View directory record Official record
Conditions
Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma Resectable, Pancreatic Ductal Adenocarcinoma, Pancreas Metastases
Interventions
High Dose Ascorbic Acid 25 g/m^2, Nanoparticle Paclitaxel protein bound 125mg/m^2, Cisplatin 25mg/m^2, Gemcitabine 1000mg/m^2, High Dose Ascorbic Acid 37.5 g/m^2, High Dose Ascorbic Acid 56.25 g/m^2, High Dose Ascorbic Acid 75 g/m^2
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 25, 2026, 4:24 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults

NCT00985673
View directory record Official record
Conditions
Influenza
Interventions
GSK2340274A, GSK2340273A, Seasonal trivalent influenza vaccine (TIV), Saline placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years to 40 Years
Enrollment
611 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
4
States / cities
Stockbridge, Georgia • Raleigh, North Carolina • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 25, 2026, 4:24 AM EDT
Completed Phase 2 Interventional Results available

Pemetrexed Disodium and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00407550
View directory record Official record
Conditions
Lung Cancer
Interventions
gemcitabine HCL, pemetrexed disodium
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Sep 25, 2026, 4:24 AM EDT
Completed Phase 3 Interventional

Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma

NCT01168791
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
doxorubicin in combination with palifosfamide-tris, doxorubicin in combination with placebo
Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
73
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Sep 25, 2026, 4:24 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

NCT03713593
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
lenvatinib, pembrolizumab, saline placebo
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
21
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 25, 2026, 4:24 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

NCT05468736
View directory record Official record
Conditions
COVID-19
Interventions
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
6 Months to 11 Years
Enrollment
3,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
47
States / cities
Little Rock, Arkansas • Anaheim, California • Bellflower, California + 41 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 25, 2026, 4:24 AM EDT
Completed Phase 1 Interventional

Gene Therapy Plus Chemotherapy in Treating Patients With Breast Cancer

NCT00004038
View directory record Official record
Conditions
Breast Cancer
Interventions
Ad5CMV-p53 gene, chemotherapy
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Sep 25, 2026, 4:24 AM EDT
Terminated Phase 3 Interventional Results available

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

NCT02626455
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Copanlisib (BAY80-6946), Placebo, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Bendamustine, Prednisone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
10
States / cities
Chandler, Arizona • West Covina, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 25, 2026, 4:24 AM EDT
Recruiting Phase 1 Interventional

Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy

NCT06065371
View directory record Official record
Conditions
Gastrointestinal Cancer
Interventions
Capecitabine, Sacituzumab govetican
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 25, 2026, 4:24 AM EDT
Terminated Phase 1 Interventional

Zoledronate in Treating Patients With Cervical Intraepithelial Neoplasia 2/3 or 3

NCT00278434
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
Zoledronate, Placebo (Saline)
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Sep 25, 2026, 4:24 AM EDT
Completed Phase 1 Interventional

3BNC117 and 10-1074 in HIV-infected Individuals

NCT02825797
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
3BNC117, 10-1074, Analytical treatment interruption, Placebo
Drug · Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Sep 25, 2026, 4:24 AM EDT
Completed Phase 1 Interventional Results available

Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption

NCT02463227
View directory record Official record
Conditions
HIV Infections
Interventions
VRC01
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Birmingham, Alabama • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Sep 25, 2026, 4:24 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

NCT00953524
View directory record Official record
Conditions
Influenza, Swine-origin A/H1N1 Influenza
Interventions
Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA), Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA), Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA), Normal saline solution (placebo)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
849 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
15
States / cities
Hoover, Alabama • Chandler, Arizona • Phoenix, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2014 · Synced Sep 25, 2026, 4:24 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae

NCT05294588
View directory record Official record
Conditions
Gonorrhea Male
Interventions
Cefixime, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090, Meningococcal Group B Vaccine, Influenza Vaccine, Tetanus-diptheria Vaccine
Drug · Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 25, 2026, 4:24 AM EDT
Terminated Phase 1 Interventional

Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma

NCT00671112
View directory record Official record
Conditions
714leukemia, Lymphoma
Interventions
Bortezomib, Everolimus
Drug
Lead sponsor
Brian Hill, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Sep 25, 2026, 4:24 AM EDT
Terminated Phase 2 Interventional Results available

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)

NCT04863248
View directory record Official record
Conditions
Metastatic Non-Small Cell Lung Cancer, NSCLC, Lung Cancer
Interventions
Trilaciclib, Placebo, Docetaxel
Drug
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Rancho Mirage, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Sep 25, 2026, 4:24 AM EDT
Terminated Phase 2 Interventional Results available

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

NCT05113966
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Trilaciclib, Sacituzumab Govitecan-hziy
Drug
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
22
States / cities
Chandler, Arizona • Bakersfield, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Sep 25, 2026, 4:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety and Immunogenicity of H1N1 Vaccine

NCT01177202
View directory record Official record
Conditions
H1N1 Flu
Interventions
HAC1 Vaccine
Biological
Lead sponsor
Fraunhofer, Center for Molecular Biotechnology
Industry
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Sep 25, 2026, 4:24 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study

NCT03298867
View directory record Official record
Conditions
Thyroid Eye Disease, Graves' Orbitopathy
Interventions
Teprotumumab, Placebo
Biological · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
9
States / cities
Beverly Hills, California • Los Angeles, California • Coral Gables, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Sep 25, 2026, 4:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pandemic Influenza Plasmid DNA Vaccines (Needle-Free)

NCT00694213
View directory record Official record
Conditions
Influenza
Interventions
VCL-IPM1, VCL-IPT1, PBS
Biological
Lead sponsor
Vical
Industry
Eligibility
18 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
3
States / cities
San Diego, California • Baltimore, Maryland • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Sep 25, 2026, 4:24 AM EDT
Completed Phase 2 Interventional Results available

Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma

NCT02428192
View directory record Official record
Conditions
Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma, Uterine Corpus Leiomyosarcoma
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Sep 25, 2026, 4:24 AM EDT
Completed Phase 2 Interventional

Tocilizumab in Cardiac Transplantation

NCT03644667
View directory record Official record
Conditions
Heart Transplant
Interventions
tocilizumab, Placebo, Standard of Care Triple IS
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
20
States / cities
Beverly Hills, California • La Jolla, California • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 25, 2026, 4:24 AM EDT